This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

McKesson Announces New President Of U.S. Pharmaceutical Business

McKesson Corporation (NYSE: MCK) today announced that Mark Walchirk has been named president, McKesson U.S. Pharmaceutical, effective immediately. Walchirk, who was most recently chief operating officer of McKesson Specialty Health, has held numerous leadership roles at McKesson for the last 11 years, including chief operating officer of McKesson U.S. Pharmaceutical. Walchirk succeeds Brian Tyler, who was recently appointed executive vice president of corporate strategy and business development, McKesson Corporation.

Walchirk will report to Paul Julian, executive vice president and group president, McKesson Corporation. He will oversee McKesson’s largest business, which supplies branded, generic and over-the-counter pharmaceuticals and value-added business, clinical and connectivity solutions to more than 40,000 customers, including retail chains, independent retail pharmacies, hospitals, health systems, integrated delivery networks and long-term care providers.

“With past roles as chief operating officer of McKesson U.S. Pharmaceutical and McKesson Specialty Health, Mark Walchirk has deep leadership experience in our pharmaceutical distribution business and a proven track record of delivering results for our customers,” said Paul Julian, executive vice president and group president, McKesson Corporation. “Mark’s significant experience coupled with his commitment to operational excellence and our customers’ success make him the ideal choice to lead McKesson U.S. Pharmaceutical.”

Walchirk joined McKesson in 2001 and spent more than eight years in progressive leadership roles within McKesson’s U.S. Pharmaceutical business before being appointed president of McKesson Specialty Care Solutions in 2009. He led McKesson’s integration of US Oncology and assumed the role of chief operating officer for the newly combined organization, McKesson Specialty Health. In this role, he helped lead the business to record growth and introduce new solutions that empower the community patient care delivery system.

As senior vice president and chief operating officer of McKesson U.S. Pharmaceutical, Walchirk led the integration of regional distributors D&K Healthcare and McQueary Bros., contributed to the dramatic growth of McKesson’s Health Mart franchise, led the expansion of McKesson’s pharmaceutical distribution business in the institutional market, and guided McKesson to industry-leading levels of accuracy and efficiency across the company’s nationwide distribution network.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs